Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813459 | 0.83 | CYP2A6 (0.33) | CYP2A6DYRK1A | |
| SCHEMBL21295963 | 0.75 | CYP2A6 (0.37) | CYP2A6DYRK1AKDM4EPTPRCPTPN6 | |
| SCHEMBL7976209 | 0.71 | PDE10A (0.35) | CYP2A6DYRK1ACTNNB1WNT3A | |
| SCHEMBL21295630 | 0.69 | CTNNB1 (0.36) | CYP2A6DYRK1AKDM4EMEN1NPC1 | |
| SCHEMBL1392217 | 0.69 | — | — | |
| SCHEMBL164774 | 0.69 | CYP2A6 (0.50) | CYP2A6DYRK1AKDM4EMEN1NPC1 | |
| SCHEMBL19756616 | 0.69 | CYP2A6 (0.42) | CYP2A6DYRK1AKDM4EMEN1NPC1 | |
| SCHEMBL21300585 | 0.67 | DYRK1A (0.36) | CYP2A6DYRK1AKDM4ENPC1RAB9A | |
| SCHEMBL153350 | 0.67 | CYP2A6 (0.50) | CYP2A6DYRK1AKDM4EMEN1NPC1 | |
| SCHEMBL1392832 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-09-04 | — | — | US | disclosed |
| US-8765782-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-01 | — | — | US | disclosed |
| US-8394971-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| CN-102091068-B | Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2012-09-19 | — | — | CN | disclosed |
| CN-1980934-B | Novel indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV | 2011-10-26 | — | — | CN | disclosed |
| EP-1771413-B1 | BENZOFURAN DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-21 | — | — | EP | disclosed |
| CN-102091068-A | Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2011-06-15 | — | — | CN | disclosed |
| CN-1980891-B | Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2011-03-09 | — | — | CN | disclosed |
| CN-1980917-A | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1771413-A2 | INDOLE, BENZOFURAN AND BENZOTHIPHENE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1756109-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753749-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005110985-A2 | INDOLE, BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111042-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111028-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | AR, NR5A1, FSHR | CYP2A6 426/4885DYRK1A 3191/4885KDM4E 816/4885 |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | CYP2A6 361/4885DYRK1A 614/4885KDM4E 1287/4885 |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | CYP2A6 361/4885DYRK1A 614/4885KDM4E 1287/4885 |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | AR, NR5A1, NR5A2 | CYP2A6 346/4885DYRK1A 651/4885KDM4E 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.